Immunogenicity of human interferon-beta-containing pharmaceuticals
- Authors: Nazarov V.D.1, Lapin S.V.1, Mazing A.V.1, Evdoshenko E.P.2, Totolian A.A.1,3
-
Affiliations:
- Center for Molecular Medicine
- Saint-Petersburg Center of Multiple Sclerosis and Autoimmune Diseases Clinical Hospital No. 31
- Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology (St. Petersburg Pasteur Institute)
- Issue: Vol 81, No 11 (2016)
- Pages: 1396-1400
- Section: Molecular and Cellular Mechanisms of Inflammation (Special Issue) Guest Editors S. A. Nedospasov and D. V. Kuprash
- URL: https://journals.rcsi.science/0006-2979/article/view/151118
- DOI: https://doi.org/10.1134/S000629791611016X
- ID: 151118
Cite item
Abstract
Multiple sclerosis is a severe autoimmune disease with inflammatory component that continues to be resistant to treatment. One of the approaches retarding its progression is based on using nonspecific therapy with human interferon-beta (IFN-β)-containing pharmaceuticals. Neutralizing antibodies (NAbs) against genetically engineered pharmaceuticals developed by the patient’s immune system, which reduce their therapeutic and biological activity, pose a serious problem. Cell lines sensitive to IFN-β activity also quantifying NAb level are applied because direct measurement of IFN-β antiviral activity is complicated. This study was aimed at standardization and validation of a reporter cell system for measuring antihuman IFN-β NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis.
About the authors
V. D. Nazarov
Center for Molecular Medicine
Author for correspondence.
Email: Nazarov19932@mail.ru
Russian Federation, St. Petersburg, 197022
S. V. Lapin
Center for Molecular Medicine
Email: Nazarov19932@mail.ru
Russian Federation, St. Petersburg, 197022
A. V. Mazing
Center for Molecular Medicine
Email: Nazarov19932@mail.ru
Russian Federation, St. Petersburg, 197022
E. P. Evdoshenko
Saint-Petersburg Center of Multiple Sclerosis and Autoimmune Diseases Clinical Hospital No. 31
Email: Nazarov19932@mail.ru
Russian Federation, St. Petersburg, 197110
A. A. Totolian
Center for Molecular Medicine; Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology (St. Petersburg Pasteur Institute)
Email: Nazarov19932@mail.ru
Russian Federation, St. Petersburg, 197022; St. Petersburg, 197101